ArticleBritish journal of cancer2010

Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.

C Charbonneau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.